Last Updated : May 3, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Relpax | Eletriptan hydrobromide | Migraine | Do not list | Complete | ||
| Botox | onabotulinumtoxinA | Migraine, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Nurtec ODT | rimegepant | Migraine, prevention | Withdrawn | |||
| Qulipta | atogepant | Migraine, prevention | Active | |||
| Qulipta | atogepant | Migraine, prevention | Reimburse with clinical criteria and/or conditions | Complete | ||
| Paxlovid | nirmatrelvir/ritonavir | Mild-to-moderate COVID-19, treatment | Reimburse with clinical criteria and/or conditions | Active | ||
| Blincyto | Blinatumomab | MRD+ ALL Resubmission | Reimburse with clinical criteria and/or conditions | Complete | ||
| Keytruda | Pembrolizumab | MUC First line | Do not reimburse | Complete | ||
| Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vimizim | Elosulfase alfa | Mucopolysaccharidosis IVA (Morquio A syndrome) | Do not list | Complete |
Last Updated : May 3, 2024